UK drugmaker Martindale Pharma on Wednesday said it has opened a scientific office in the Kingdom of Saudi Arabia (KSA) in line with its strategy to market its portfolio in potential high-growth markets saying this is a key step towards growing sales.
The company also named Dr Fahad Al Showaier as scientific office manager.
The new office will be responsible for obtaining marketing approvals for the company’s products with the Saudi Federal Drug Agency (SFDA), the regulatory agency of Saudi Arabia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze